Personalized Medicine: Does the Molecular Suit Fit?
Edison Liu and Patrick Johnston
This roundtable highlights the increasing importance of genetic context in our treatment algorithms for solid tumors, as exemplified by the role of RAS mutational testing in concert with therapeutic targeting of the epidermal growth factor receptor in colorectal cancer. Liu and Johnston emphasize the need for coordinated therapeutic and diagnostic innovation pipelines, with new therapies and their diagnostics linked at the level of development, approval, clinical application and reimbursement. A coordinated approach is the cornerstone of the robust functioning of a personalized cancer medicine agenda, meeting the need to develop new models of partnership in the academia-industry intersect.